Tocilizumab(Roche / Genentech)은 Chronic Lymphocytic Leukemia 표적 항체로, Multiple Myeloma (MM); Multiple Myeloma Refractory 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 95% (ClinicalTrials.gov NCT03677141). PK: t½ 3.4 h. 차별점: novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity.
Chronic Lymphocytic Leukemia
Multiple Myeloma (MM); Multiple Myeloma Refractory
Recruiting
CAR-T) therapies are approved for refractory and relapsed multipl
humanized mouse model
novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity
checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo
cytokine release syndrome (CRS) demonstrated a 20-30% major cardiovascular adverse event (MACE) rate
apoptosis
biomarker for predicting treatment response in RA patients
resistance to first- and second-line therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Tocilizumab(Roche / Genentech)은 Chronic Lymphocytic Leukemia 표적 항체로, Multiple Myeloma (MM); Multiple Myeloma Refractory 영역에서 개발·상용화 중입니다. 작용기전: checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo. FDA 승인 또는 승인 단계 프로그램입니다. 대표 임상 효능: ORR 95% (ClinicalTrials.gov NCT03677141). PK: t½ 3.4 h. 차별점: novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity.
Chronic Lymphocytic Leukemia
Multiple Myeloma (MM); Multiple Myeloma Refractory
Recruiting
CAR-T) therapies are approved for refractory and relapsed multipl
humanized mouse model
novel directions and drug candidates for the treatment of CAR-T cell therapy-induced myocardial toxicity
checkpoint inhibitor-induced inflammatory arthritis (ICI-IA) is an immune-related adverse event (irAE) follo
cytokine release syndrome (CRS) demonstrated a 20-30% major cardiovascular adverse event (MACE) rate
apoptosis
biomarker for predicting treatment response in RA patients
resistance to first- and second-line therapies
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.